Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Amr Morsy

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	13.8yrs
CEO 소유권	2.2%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	7.8yrs

최근 관리 업데이트

Recent updates

CEO

Amr Morsy

13.8yrs

테뉴어

Dr. Amr Abdallah Morsy serves as Chief Executive Officer at Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (formerly known as Rameda Pharmaceutical) and its Executive Direc...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Amr Morsy	CEO & Executive Director	13.8yrs	데이터 없음	2.23% EGP 112.9m
Mahmoud Mustafa Salaheddine Fayek	Group CFO & Executive Director	5.8yrs	데이터 없음	0.24% EGP 12.2m
Hatem Ahmed Al Suleiman	Independent Non-Executive Director	5.8yrs	데이터 없음	데이터 없음
Shamel Aboul Fadl	Non-Executive Vice Chairman	13.8yrs	데이터 없음	0.00053% EGP 26.9k
Ayman Mamdouh Mohamed Abbas	Non-Executive Chairman of the Board	13.8yrs	데이터 없음	0.00053% EGP 26.9k
Mohamed Farouk	Non-Executive Director	8.8yrs	데이터 없음	데이터 없음
Karim Zahran	Non-Executive Director	8.8yrs	데이터 없음	데이터 없음
Tarek Abdelrahman	Non-Executive Director	6.8yrs	데이터 없음	데이터 없음
Mirna Essam Eldin Arif	Independent Non-Executive Director	1.7yrs	데이터 없음	데이터 없음
Mohamed El Shoura	Non-Executive Director	2.1yrs	데이터 없음	데이터 없음

7.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: RMDA 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 20%

Now 24% overvalued after recent price rise

New major risk - Earnings quality

New major risk - Earnings quality

Second quarter 2024 earnings released: EPS: ج.م0.039 (vs ج.م0.033 in 2Q 2023)

Now 20% overvalued

Consensus EPS estimates fall by 33%

Now 23% overvalued

Now 24% overvalued

Price target increased by 15% to ج.م4.38

First quarter 2024 earnings released: EPS: ج.م0.038 (vs ج.م0.045 in 1Q 2023)

Consensus revenue estimates increase by 13%

Price target increased by 12% to ج.م3.47

Full year 2023 earnings released: EPS: ج.م0.15 (vs ج.م0.15 in FY 2022)

New minor risk - Market cap size

Price target increased by 24% to ج.م2.96

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

New major risk - Financial position

New major risk - Earnings quality

Price target increased by 7.3% to ج.م3.74

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Now 22% undervalued

Price target increased to ج.م3.32

Less than half of directors are independent

Price target decreased to ج.م3.07

Second quarter 2022 earnings released: EPS: ج.م0.053 (vs ج.م0.032 in 2Q 2021)

Less than half of directors are independent

Price target decreased to ج.م3.23

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to ج.م3.16

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS ج.م0.041 (vs ج.م0.026 in 2Q 2020)

Price target decreased to ج.م4.85

Consensus EPS estimates fall to ج.م0.21

Full year 2020 earnings released

Revenue beats expectations, earnings disappoint

New 90-day low: ج.م3.25

New 90-day low: ج.م3.46

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS ج.م0.032

New 90-day low: ج.م3.54

New 90-day low: ج.م3.60

Analysts update estimates

Earnings released

Analysts update estimates

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령